STOCK TITAN
  1. Home
  2. News
  3. TSHA

Taysha Gene Therapies Inc - TSHA STOCK NEWS

Welcome to our dedicated news page for Taysha Gene Therapies (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taysha Gene Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taysha Gene Therapies's position in the market.

News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Taysha Gene Therapies, Inc. granted three new employees options to purchase 140,000 shares of common stock at $2.84 per share under the 2023 Inducement Plan. The options have a 10-year term, vesting over four years, with 25% on the first anniversary and the remaining 75% over the following 36 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
News
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Rhea-AI Summary
Taysha Gene Therapies, Inc. reports positive clinical data from the REVEAL Phase 1/2 trial of TSHA-102 for Rett syndrome, showcasing sustained improvements in patients with no serious adverse events. The company also provided financial results for 2023 and future milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.56%
Tags
earnings
-
News
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
Rhea-AI Summary
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) will report its financial results for the full-year ended December 31, 2023. The company focuses on developing AAV-based gene therapies for severe monogenic diseases of the CNS. A corporate update conference call is scheduled for March 19, 2024, at 4:30 PM Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.48%
Tags
earnings
News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Taysha Gene Therapies, Inc. granted four new employees options to purchase 347,000 shares of the Company's common stock under the 2023 Inducement Plan. The options have an exercise price of $3.23 per share and will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
News
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
Rhea-AI Summary
Taysha Gene Therapies, Inc. announces advancement in REVEAL adolescent and adult trial for Rett syndrome treatment. The high dose cohort will proceed following IDMC approval. Expansion into the U.S. and dosing updates expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.7%
Tags
none
-
News
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
Rhea-AI Summary
Taysha Gene Therapies, Inc. provides an update on its deprioritized pipeline programs, including transferring rights and materials to third parties for continued development. The company terminated an existing loan agreement, extended its cash runway, and made progress on various programs. Taysha aims to advance important development work for several deprioritized programs while focusing on its lead program for Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.13%
Tags
none
News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Taysha Gene Therapies, Inc. granted two new employees options to purchase 180,000 shares of the Company's common stock. The stock options were granted under the 2023 Inducement Plan and have an exercise price of $1.56 per share. The options will vest over four years, subject to continued service to Taysha.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
none
-
News
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
Rhea-AI Summary
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) will present clinical data on its TSHA-102 program for Rett syndrome at the British Paediatric Neurology Association (BPNA) 2024 Annual Conference. The presentation will include previously disclosed clinical data from the first two adult patients with stage four Rett syndrome dosed with TSHA-102 in the REVEAL Phase 1/2 adolescent and adult trial in Canada. The Company expects to provide further updates on available clinical data from cohort one (low dose) in the REVEAL trial in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
News
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Rhea-AI Summary
Taysha Gene Therapies, a clinical-stage gene therapy company (Nasdaq: TSHA), broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome in the U.S. and U.K. The initial safety and efficacy data for the REVEAL pediatric trial is expected in mid-2024. TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
clinical trial
News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the granting of 257,700 shares of common stock to Meredith Schultz, M.D., M.S., as an inducement for her employment as the new Senior Vice President, Clinical Development and Medical Affairs. The stock option has an exercise price of $1.71 per share, with a 10-year term and will vest over four years. This announcement was made in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
Stock TSHA logo
Taysha Gene Therapies Inc

Nasdaq:TSHA

TSHA Rankings

#3074 Ranked by Market Cap
#681 Ranked by Stock Gains
N/A Ranked by Dividends

TSHA Stock Data

549.83M
100.06M
24.77%
69.83%
9.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Dallas

About TSHA

taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.